Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;148(2):363-77.
doi: 10.1007/s10549-014-3157-6. Epub 2014 Oct 10.

Metabolic syndrome and outcomes following early-stage breast cancer

Gregory S Calip  1 , Kathleen E Malone, Julie R Gralow, Andy Stergachis, Rebecca A Hubbard, Denise M Boudreau
Affiliations

Metabolic syndrome and outcomes following early-stage breast cancer

Gregory S Calip et al. Breast Cancer Res Treat. 2014 Nov.

Abstract

The prevalence of risk factors contributing to metabolic syndrome (MetS) is increasing, and numerous components of MetS are associated with increased primary breast cancer (BC) risk. However, less is known about the relationship of MetS to BC outcomes. The aim of this study was to evaluate whether MetS, characterized by increased weight, hypertension, low HDL-cholesterol, high triglycerides, and diabetes or impaired glucose tolerance, is associated with risk of second breast cancer events (SBCE) and BC-specific mortality. Retrospective cohort study of women diagnosed with incident early-stage (I-II) BC between 1990 and 2008, enrolled in an integrated health plan. Outcomes of interest were SBCE, defined as recurrence or second primary BC, and BC-specific mortality. We used multivariable Cox proportional hazards models to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for time-varying exposure to MetS components while accounting for potential confounders and competing risks. Among 4,216 women in the cohort, 26% had ≥3 MetS components and 13% developed SBCE during median follow-up of 6.3 years. Compared to women with no MetS components, presence of MetS (≥3 components) was associated with increased risk of SBCE (HR = 1.50, 95% CI 1.08-2.07) and BC-specific mortality (HR = 1.65, 95% CI 1.02-2.69). Of the individual components, only increased weight was associated with increased risk of SBCE (HR = 1.26, 95% CI 1.06-1.49). MetS is associated with modestly increased risk of SBCE and BC-specific mortality. Given the growing population of BC survivors, further research in larger and more diverse populations is warranted.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Patient flow diagram showing Group Health Cooperative (GH) selection of women with stage I or II breast cancer diagnosed between 1990 and 2008 to the Commonly Used Medications and Breast Cancer Outcomes (COMBO) study cohort
Figure 2
Figure 2. Adjusted hazard ratios and 95% confidence intervals for the relation between number of metabolic syndrome components with risk of SBCE, breast cancer-specific mortality and overall mortality
Note: Reference group for all estimates is 0 MetS components. Hazard ratios are adjusted for age (18–39, 40–49, 50–59, 60–69, 70–79, 80+ years), incident breast cancer diagnosis year, AJCC stage (I, IIA, IIB), hormone receptor status (ER−/PR−, ER+/PR−, ER−/PR+, ER+/PR+), primary treatment for the initial breast cancer (mastectomy +/− radiation, BCS + radiation, BCS), chemotherapy (yes/no), endocrine therapy (yes/no, time-varying), race (White, African American, American Indian/Alaska Native, Asian/Pacific Islander, unknown), smoking status (current, past, never), menopausal status (pre- or perimenopausal, postmenopausal), receipt of surveillance mammography (yes/no in prior 12 months, time-varying) as categorical variables; accounting for competing risks in multivariate-adjusted models. Tables of risk estimates with number of events and person-years in Online Resource 3 and 4.
Figure 3
Figure 3. Adjusted hazard ratios and 95% confidence intervals for the relation between individual metabolic syndrome components and risk of SBCE, breast cancer-specific mortality and overall mortality
Note: Hazard ratios are adjusted for age (18–39, 40–49, 50–59, 60–69, 70–79, 80+ years), incident breast cancer diagnosis year, AJCC stage (I, IIA, IIB), hormone receptor status (ER−/PR−, ER+/PR−, ER−/PR+, ER+/PR+), primary treatment for the initial breast cancer (mastectomy +/− radiation, BCS + radiation, BCS), chemotherapy (yes/no), endocrine therapy (yes/no, time-varying), race (White, African American, American Indian/Alaska Native, Asian/Pacific Islander, unknown), smoking status (current, past, never), menopausal status (pre- or perimenopausal, postmenopausal), receipt of surveillance mammography (yes/no in prior 12 months, time-varying) as categorical variables; accounting for competing risks in multivariate-adjusted models. Tables of risk estimates with number of events and person-years in Online Resource 3 and 4.
Figure 3
Figure 3. Adjusted hazard ratios and 95% confidence intervals for the relation between individual metabolic syndrome components and risk of SBCE, breast cancer-specific mortality and overall mortality
Note: Hazard ratios are adjusted for age (18–39, 40–49, 50–59, 60–69, 70–79, 80+ years), incident breast cancer diagnosis year, AJCC stage (I, IIA, IIB), hormone receptor status (ER−/PR−, ER+/PR−, ER−/PR+, ER+/PR+), primary treatment for the initial breast cancer (mastectomy +/− radiation, BCS + radiation, BCS), chemotherapy (yes/no), endocrine therapy (yes/no, time-varying), race (White, African American, American Indian/Alaska Native, Asian/Pacific Islander, unknown), smoking status (current, past, never), menopausal status (pre- or perimenopausal, postmenopausal), receipt of surveillance mammography (yes/no in prior 12 months, time-varying) as categorical variables; accounting for competing risks in multivariate-adjusted models. Tables of risk estimates with number of events and person-years in Online Resource 3 and 4.
Figure 3
Figure 3. Adjusted hazard ratios and 95% confidence intervals for the relation between individual metabolic syndrome components and risk of SBCE, breast cancer-specific mortality and overall mortality
Note: Hazard ratios are adjusted for age (18–39, 40–49, 50–59, 60–69, 70–79, 80+ years), incident breast cancer diagnosis year, AJCC stage (I, IIA, IIB), hormone receptor status (ER−/PR−, ER+/PR−, ER−/PR+, ER+/PR+), primary treatment for the initial breast cancer (mastectomy +/− radiation, BCS + radiation, BCS), chemotherapy (yes/no), endocrine therapy (yes/no, time-varying), race (White, African American, American Indian/Alaska Native, Asian/Pacific Islander, unknown), smoking status (current, past, never), menopausal status (pre- or perimenopausal, postmenopausal), receipt of surveillance mammography (yes/no in prior 12 months, time-varying) as categorical variables; accounting for competing risks in multivariate-adjusted models. Tables of risk estimates with number of events and person-years in Online Resource 3 and 4.
Figure 3
Figure 3. Adjusted hazard ratios and 95% confidence intervals for the relation between individual metabolic syndrome components and risk of SBCE, breast cancer-specific mortality and overall mortality
Note: Hazard ratios are adjusted for age (18–39, 40–49, 50–59, 60–69, 70–79, 80+ years), incident breast cancer diagnosis year, AJCC stage (I, IIA, IIB), hormone receptor status (ER−/PR−, ER+/PR−, ER−/PR+, ER+/PR+), primary treatment for the initial breast cancer (mastectomy +/− radiation, BCS + radiation, BCS), chemotherapy (yes/no), endocrine therapy (yes/no, time-varying), race (White, African American, American Indian/Alaska Native, Asian/Pacific Islander, unknown), smoking status (current, past, never), menopausal status (pre- or perimenopausal, postmenopausal), receipt of surveillance mammography (yes/no in prior 12 months, time-varying) as categorical variables; accounting for competing risks in multivariate-adjusted models. Tables of risk estimates with number of events and person-years in Online Resource 3 and 4.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Cancer Society. Breast Cancer Facts & Figures 2013–2014. Atlanta: American Cancer Society, Inc; 2013.
    1. American Cancer Society. Cancer Treatment and Survivorship Facts & Figures 2012–2013. Atlanta: American Cancer Society, Inc; 2012.
    1. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE American Society of Clinical O. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31 (7):961–965. doi: 10.1200/JCO.2012.45.9859. - DOI - PubMed
    1. Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract. 2011;7 (6):371–374. doi: 10.1200/JOP.2011.000460. - DOI - PMC - PubMed
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr, Spertus JA, Costa F American Heart A, National Heart L Blood I. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112 (17):2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404. - DOI - PubMed

Publication types

MeSH terms